Provided is a method of treating cancer in an individual by administering to the individual modified cells that express a chimeric antigen receptor (CAR) that contain a TIGIT extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3 segment. The modified cells may co-express and secrete a Bi-specific T cell engager (BiTE). The BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FR) and a segment that that can specifically bind to a human CD3 segment. Modified cells that express the CAR, and may also express and secrete the BiTE, and polynucleotides encoding the CAR and the BiTE, are also provided.

Provided is a polymer compound comprising: a hydrophobic moiety binding to natural killer (NK) cells; a cancer cell recognition moiety; and a linker, wherein the hydrophobic moiety is bound to one end of the linker and the cancer cell recognition moiety is bound to the other end of the linker and recognizes NK cells and cancer cells, wherein the cancer cell recognition moiety comprises hyaluronic acid.